Open AccessDETECTION OF AUTOANTIBODIES RECOGNIZING CANCERRETINA ANTIGEN RECOVERIN IN BLOOD OF PATIENTS WITH NON-INVASIVE FOLLICULAR THYROID NEOPLASMS WITH PAPILLARY-LIKE NUCLEAR FEATURES (NIFTP)
Author(s) -
Pavel V. Belousov,
Яна Игоревна Бобровская,
Аполлинария Васильевна Боголюбова,
Алексей Юрьевич Сазыкин,
Юрий Владимирович Шебзухов,
Антон Маркович Шварц,
K V Lanshchakov,
В Э Ванушко,
Dmitry V. Kuprash,
Александр Юрьевич Абросимов
Publication year - 2019
Publication title -
medicinskaâ immunologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.133
H-Index - 6
eISSN - 2313-741X
pISSN - 1563-0625
DOI - 10.15789/1563-0625-2019-4-781-788
Subject(s) - recoverin , medicine , biomarker , pathology , thyroid neoplasm , papillary thyroid cancer , thyroid , pathological , thyroid cancer , follicular phase , oncology , retinal , biology , ophthalmology , biochemistry , rhodopsin
Autoantibodies recognizing the cancer-retina autoantigen called recoverin (RCVRN-AutoAb) may serve as a highly specific biomarker of cancer-associated retinopathy. However, they may also be found in some cancer patients without clinical evidence of retinopathy. In the present study, dot-ELISA and Western blot assays were used to demonstrate the presence of circulating RCVRN-AutoAb in 4/7 (57%) of patients with recently recognized pathological entity, non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP); other thyroid tumors represented by follicular adenomas, and classical and follicular variants of papillary thyroid carcinomas, demonstrated low frequencies of RCVRN-AutoAb (0/15, 1/20 (5%) and 1/15 (7%), respectively), with no significant differences from healthy individuals (0/15). Our data implicate the circulating RCVRN-AutoAb as a potential biomarker of NIFTP capable of discrimination of this novel pathological entity from other thyroid tumors.